Assessing Bio-Techne (TECH) Valuation After Mixed Long Term Shareholder Returns

Bio-Techne stock: recent performance snapshot

Bio-Techne (TECH) has drawn investor attention after a mixed stretch, with a small gain over the past month alongside a decline over the past 3 months and weaker multi year total returns.

Against that backdrop, the stock last closed at US$54.74, with annual revenue of US$1.22b and net income of US$81.06m. This positions the company as a mid cap player in life science tools and diagnostics.

See our latest analysis for Bio-Techne.

Short term momentum has softened, with a 30 day share price return of 3.03% set against a 90 day share price return decline of 15.30% and a 5 year total shareholder return decline of 45.20%, which indicates sentiment has cooled compared to earlier years.

If you are comparing Bio-Techne with other opportunities, this could be a moment to see what else is moving in healthcare and biotech through 33 healthcare AI stocks

With Bio-Techne trading at US$54.74 alongside a value score of 3 and indicators of intrinsic and target price discounts, you need to ask: Is the stock currently undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 27.3% Undervalued

Bio-Techne's most followed narrative pegs fair value at US$75.25 per share, meaning the current US$54.74 price sits well below that estimate and frames the stock as undervalued within this framework.

The growing prevalence of chronic and age-related diseases globally, alongside an aging population, is driving sustained demand for advanced diagnostics and therapeutics where Bio-Techne's reagents and tools are embedded. This trend supports recurring consumables revenue and long-term top-line growth even as short-term funding uncertainties persist.

Read the complete narrative.

Want to see what is baked into that higher fair value? The narrative focuses on steady revenue compounding, margin rebuild from current levels, and a richer future earnings multiple. Curious how those pieces fit together across the next few years and result in a fair value that is well above today's price? The full narrative lays out the assumptions in detail.

Result: Fair Value of $75.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh the risk that weaker biotech and academic funding, or tougher tariffs and regulation, could cap demand and pressure margins.

Find out about the key risks to this Bio-Techne narrative.

Another Way to Look at Value

While the SWS DCF model suggests Bio-Techne is trading about 24.9% below an estimated fair value of US$72.86, the P/E ratio tells a very different story. At 105.7x earnings versus a fair ratio of 22.5x, the stock is also priced well above the Global Life Sciences average of 35.3x and a peer average of 28x, which flags meaningful valuation risk if sentiment or growth expectations cool. Which signal do you put more weight on?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment looking mixed, now is a good time to slow down, review the numbers yourself, and decide how you see the balance of risk and reward given the company's weaker long term returns but also the upside case some investors see in recurring revenues and potential margin rebuild, starting with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Bio-Techne has caught your attention, do not stop here. Use these tools to spot other opportunities that could fit your goals before the crowd does.

• Target potential value opportunities early by scanning companies that screen as 48 high quality undervalued stocks based on their fundamentals and price.
• Prioritise resilience by checking out 70 resilient stocks with low risk scores so you can focus on stocks with historically lower risk scores.
• Hunt for potential future standouts by reviewing the screener containing 25 high quality undiscovered gems that rarely show up on mainstream radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com